NLS Pharmaceutics

60 articles with NLS Pharmaceutics

• NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2

  3/27/2023

  NLS Pharmaceutics Ltd. today announced the final results from its Open Label Extension (OLE) Study for Quilience® (Mazindol ER) in the treatment of narcolepsy.

• NLS Pharmaceutics to Present at the 35th Annual Roth Conference

  3/1/2023

  NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced Alex Zwyer, CEO, will be presenting at the 35th Annual Roth Conference.

• NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy

  1/30/2023

  NLS Pharmaceutics Ltd. today announced the completion of the POLARIS six-month open-label extension study (NLS-1022) with Mazindol ER in patients with narcolepsy.

• NLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement

  1/25/2023

  NLS Pharmaceutics Ltd. today announced that it received a notification letter from the Hearings Panel of The Nasdaq Stock Market LLC notifying the Company that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least $2,500,000.

• NLS Pharmaceutics Announces New In-Vitro Data Reconfirming Quilience's(R) (Mazindol ER) Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity

  1/23/2023

  NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced new in vitro study results demonstrating the agonist effect of mazindol ER at the Orexin-2 Receptor (OX2R).

• NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical Compounds

  1/12/2023

  NLS Pharmaceutics Ltd. today announced plans to showcase its global strategic R&D progress and platform, as well as its product candidate and pipeline goals for 2023, with a focus on rare and complex CNS disorders with unmet medical needs.

• NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement

  1/12/2023

  NLS Pharmaceutics Ltd. today announced that it received a notification letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC notifying the Company that it has regained compliance with the Nasdaq's minimum bid price requirement.

• NLS Pharmaceutics to Participate in Upcoming Investor Conferences - January 11, 2023

  1/11/2023

  NLS Pharmaceutics Ltd. is pleased to announce its participation in the following upcoming conferences: 2023 BIO CEO Investor Conference.

• NLS Pharmaceutics CEO Issues Letter to Shareholders - December 22, 2022

  12/22/2022

  NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders:

• NLS Pharmaceutics Announces Israeli Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Other Sleep Disorders Through 2037

  12/20/2022

  NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that the Israeli Patent Office has granted approval for Patent Application 261418, which covers Mazindol as a method of treatment for Attention Deficit/Hyperactivity Disorder (ADHD).

• NLS Pharmaceutics Announces Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P.

  12/14/2022

  NLS Pharmaceutics Ltd. announced the closing of its previously publicized purchase agreement with BVF Partners L.P. comprised of an initial closing of $10 million in exchange for 11,494,253 common shares, representing a purchase price per share of $0.87.

• NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification - December 7, 2022

  12/7/2022

  NLS Pharmaceutics Ltd. today announced that it had received a written notice from The Nasdaq Stock Market LLC, indicating that the Company was not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of $1.00 per share.

• NLS Pharmaceutics Announces Purchase Agreement with BVF Partners L.P. to Raise Aggregate Gross Proceeds of up to $30 Million

  12/7/2022

  NLS Pharmaceutics Ltd. today announced that it has entered into a definitive agreement with BVF Partners L.P. to raise aggregate gross proceeds of up to $30.0 million in a two-tranche private placement.

• NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder

  12/1/2022

  NLS Pharmaceutics Ltd. today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application 16/645,306.

• NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing

  10/5/2022

  NLS Pharmaceutics Ltd. announces that on September 29, 2022, it received a determination letter of the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company of the Staff's determination that, unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the "Panel"), the Company's securities would be subject to delisting from The Nasdaq Capital Market

• NLS Pharmaceutics Announces $4 Million Private Placement and Conversion of Existing Short-Term Notes

  10/3/2022

  NLS Pharmaceutics Ltd. announces that it has entered into definitive agreements with investors, alongside participation from the Company's Chairman of the Board of Directors, Ronald Hafner, and George Apostol, the Company's recently appointed Chief Medical Officer, for the purchase and sale on a private placement basis of 5,194,802 of its common shares.

• NLS Pharmaceutics Announces Positive Top-Line Results from its Phase 2a Clinical Trial of Once-Daily Quilience(R) (Mazindol ER) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

  9/27/2022

  NLS Pharmaceutics Ltd. announces positive top-line results from its Phase 2a clinical trial evaluating its lead product candidate, Quilience® (Mazindol ER), in the treatment of narcolepsy.

• NLS Pharmaceutics To Host Virtual Key Opinion Leader Event on September 30, 2022 After Release of Quilience(R) Top-Line Phase 2a Narcolepsy Results

  9/19/2022

  NLS Pharmaceutics Ltd. announces that it will host a Virtual Key Opinion Leader Event to review top-line results from its Phase 2a clinical trial evaluating Quilience® (Mazindol ER) in the treatment of excessive daytime sleepiness (EDS) and cataplexy, the two core symptoms of narcolepsy.

• NLS Pharmaceutics Appoints Dr. George Apostol as Chief Medical Officer and Global Head of Research & Development

  9/8/2022

  NLS Pharmaceutics Ltd. announces that Dr. George Apostol has been appointed to the position of Chief Medical Officer and Global Head of Research and Development.

• NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release

  7/28/2022

  NLS Pharmaceutics Ltd. announces that the Japanese Patent Office (JPO) notified the Company of its decision to grant patent application 2018-546837 for the proprietary formulation of Quilience® (Mazindol ER).